Sanofi and Genzyme have announced that their new multiple sclerosis treatment Lemtrada has been approved by the European Commission.
The drug is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features and has been in active clinical development for more than ten years.
“Sanofi and Genzyme have been granted European regulatory approval for Lemtrada, their newest therapy for multiple sclerosis.“
Studies carried out among more than 1,700 patients revealed that Lemtrada can offer significant efficacy benefits compared to currently-available treatment options, with the approval of the product meaning that Genzyme can now plan its European launch.
This comes after another Sanofi/Genzyme multiple sclerosis drug, Aubagio, was also approved by the European Commission last month, with the dual approvals greatly expanding the companies' portfolio in this important medical field.
Genzyme chief executive officer and president Dr David Meeker said: "The approvals of Lemtrada and Aubagio in the EU represent an important milestone for Genzyme and demonstrate our focus on scientific innovation and commitment to multiple sclerosis patients."